(Q53482041)

14 May 2018

title

Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma. (English)

1 reference

14 May 2018

0 references

Hui Wang

1

1 reference

14 May 2018

Ying Liu

2

1 reference

14 May 2018

Xiu Wang

3

1 reference

14 May 2018

Donghui Liu

4

1 reference

14 May 2018

Zhiqiang Sun

5

1 reference

14 May 2018

Chun Wang

6

1 reference

14 May 2018

Gang Jin

7

1 reference

14 May 2018

Beiguang Zhang

8

1 reference

14 May 2018

Shilong Yu

9

1 reference

14 May 2018

language of work or name

English

0 references

publication date

29 May 2015

1 reference

14 May 2018

published in

Cancer

1 reference

14 May 2018

volume

121

1 reference

14 May 2018

issue

17

1 reference

14 May 2018

page(s)

2917-2925

1 reference

14 May 2018

Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Cancer: a Systems Biology disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Acute promyelocytic leukemia: what is the new standard of care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Effect of arsenic trioxide on human hepatocarcinoma in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

ABCG2: determining its relevance in clinical drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Identification of local and circulating cancer stem cells in human liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Novel therapeutic strategies for targeting liver cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Inhibition by arsenic trioxide of human hepatoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide treatment of rabbit liver VX-2 carcinoma via hepatic arterial cannulation-induced apoptosis and decreased levels of survivin in the tumor tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intraarterial versus intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

7 January 2021

inferred from DOI database lookup

Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

7 January 2021

inferred from DOI database lookup

Report of the 15th follow-up survey of primary liver cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29456

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/CNCR.29456

1 reference

14 May 2018

release_ef66i4xf7bhwhh7csfui7qfu7y

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ef66i4xf7bhwhh7csfui7qfu7y

24 November 2022

mapped directly with Wikidata item

1 reference

14 May 2018